SCHEMBL3019531

SCHEMBL3019531

O=S(=O)(c1cccc(C(F)(F)F)c1)C1CCN(c2nc(Cc3cc(Cl)cc(Cl)c3)cs2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 1/20 0.46
KDM4E B2RXH2 2/20 0.39
MAPT P10636 2/20 0.39
AR P10275 1/20 0.39
KDM1A O60341 1/20 0.38
ADORA2A P29274 1/20 0.38
ADORA2B P29275 1/20 0.38
ADORA1 P30542 1/20 0.38
CNR1 P21554 1/20 0.37
RAB9A P51151 2/20 0.37
NPC1 O15118 1/20 0.37
ELOVL6 Q9H5J4 1/20 0.35
GAA P10253 2/20 0.35
HPGD P15428 1/20 0.35
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
KDM2B Q8NHM5 1/20 0.35
POLB P06746 1/20 0.35
PPARG P37231 1/20 0.35
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3021306 0.96 CTSS (0.43) CTSSKDM4EMAPTARKDM1A
SCHEMBL3013043 0.94 CTSS (0.45) CTSSKDM4EMAPTARKDM1A
SCHEMBL3003290 0.91 CTSS (0.46) CTSSKDM4EMAPTARADORA2A
SCHEMBL3014445 0.91 CTSS (0.47) CTSSKDM4EMAPTARADORA2A
SCHEMBL3016518 0.91 CTSS (0.43) CTSSKDM4EMAPTARKDM1A
SCHEMBL3016859 0.91 CTSS (0.44) CTSSKDM4EMAPTARKDM1A
SCHEMBL3005492 0.90 CTSS (0.45) CTSSKDM4EMAPTARADORA2A
SCHEMBL3015941 0.90 CTSS (0.45) CTSSKDM4EMAPTARKDM1A
SCHEMBL3015263 0.89 CTSS (0.43) CTSSKDM4EMAPTARKDM1A
SCHEMBL3013306 0.89 RAB9A (0.42) KDM4EMAPTRAB9ANPC1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA CTSS 106/4885KDM4E 4398/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.